These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

208 related articles for article (PubMed ID: 7836906)

  • 1. Cells expressing a major histocompatibility complex class I molecule with a single covalently bound peptide are highly immunogenic.
    Mottez E; Langlade-Demoyen P; Gournier H; Martinon F; Maryanski J; Kourilsky P; Abastado JP
    J Exp Med; 1995 Feb; 181(2):493-502. PubMed ID: 7836906
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Induction of CTL in vivo by major histocompatibility complex class I-peptide complexes covalently associated on the cell surface.
    Anjuère F; Horvath C; Cerottini JC; Luescher IF
    Eur J Immunol; 1995 Jun; 25(6):1535-40. PubMed ID: 7614979
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The CD8+ T cell repertoire in beta 2-microglobulin-deficient mice is biased towards reactivity against self-major histocompatibility class I.
    Glas R; Ohlén C; Höglund P; Kärre K
    J Exp Med; 1994 Feb; 179(2):661-72. PubMed ID: 8294874
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Peptide loading of empty major histocompatibility complex molecules on RMA-S cells allows the induction of primary cytotoxic T lymphocyte responses.
    De Bruijn ML; Schumacher TN; Nieland JD; Ploegh HL; Kast WM; Melief CJ
    Eur J Immunol; 1991 Dec; 21(12):2963-70. PubMed ID: 1660811
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Role of conserved regions of class I MHC molecules in the activation of CD8+ cytotoxic T lymphocytes by peptide and purified cell-free class I molecules.
    Takeshita T; Kozlowski S; England RD; Brower R; Schneck J; Takahashi H; DeLisi C; Margulies DH; Berzofsky JA
    Int Immunol; 1993 Sep; 5(9):1129-38. PubMed ID: 8241055
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A single-chain fusion molecule consisting of peptide, major histocompatibility gene complex class I heavy chain and beta2-microglobulin can fold partially correctly, but binds peptide inefficiently.
    Sylvester-Hvid C; Nielsen LL; Hansen NJ; Pedersen LO; Buus S
    Scand J Immunol; 1999 Oct; 50(4):355-62. PubMed ID: 10520174
    [TBL] [Abstract][Full Text] [Related]  

  • 7. An efficient and versatile mammalian viral vector system for major histocompatibility complex class I/peptide complexes.
    Kawana-Tachikawa A; Tomizawa M; Nunoya J; Shioda T; Kato A; Nakayama EE; Nakamura T; Nagai Y; Iwamoto A
    J Virol; 2002 Dec; 76(23):11982-8. PubMed ID: 12414940
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Heat shock fusion proteins as vehicles for antigen delivery into the major histocompatibility complex class I presentation pathway.
    Suzue K; Zhou X; Eisen HN; Young RA
    Proc Natl Acad Sci U S A; 1997 Nov; 94(24):13146-51. PubMed ID: 9371814
    [TBL] [Abstract][Full Text] [Related]  

  • 9. IFN-gamma-induced recognition of the antigen-processing variant CMT.64 by cytolytic T cells can be replaced by sequential addition of beta 2 microglobulin and antigenic peptides.
    Jefferies WA; Kolaitis G; Gabathuler R
    J Immunol; 1993 Sep; 151(6):2974-85. PubMed ID: 8397249
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Soluble class I MHC with beta2-microglobulin covalently linked peptides: specific binding to a T cell hybridoma.
    White J; Crawford F; Fremont D; Marrack P; Kappler J
    J Immunol; 1999 Mar; 162(5):2671-6. PubMed ID: 10072510
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cytosolic targeting of hen egg lysozyme gives rise to a short-lived protein presented by class I but not class II major histocompatibility complex molecules.
    Calin-Laurens V; Forquet F; Mottez E; Kanellopoulos J; Godeau F; Kourilsky P; Gerlier D; Rabourdin-Combe C
    Eur J Immunol; 1991 Mar; 21(3):761-9. PubMed ID: 2009914
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Production of soluble MHC class II proteins with covalently bound single peptides.
    Kozono H; White J; Clements J; Marrack P; Kappler J
    Nature; 1994 May; 369(6476):151-4. PubMed ID: 8177320
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Reconstitution of antigen presentation in HLA class I-negative cancer cells with peptide-beta2m fusion molecules.
    Tafuro S; Meier UC; Dunbar PR; Jones EY; Layton GT; Hunter MG; Bell JI; McMichael AJ
    Eur J Immunol; 2001 Feb; 31(2):440-9. PubMed ID: 11180108
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Structural Definition of Duck Major Histocompatibility Complex Class I Molecules That Might Explain Efficient Cytotoxic T Lymphocyte Immunity to Influenza A Virus.
    Wu Y; Wang J; Fan S; Chen R; Liu Y; Zhang J; Yuan H; Liang R; Zhang N; Xia C
    J Virol; 2017 Jul; 91(14):. PubMed ID: 28490583
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In vitro priming of cytotoxic T lymphocytes against poorly immunogenic epitopes by engineered antigen-presenting cells.
    Bellone M; Iezzi G; Manfredi AA; Protti MP; Dellabona P; Casorati G; Rugarli C
    Eur J Immunol; 1994 Nov; 24(11):2691-8. PubMed ID: 7525300
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Qa-1 interaction and T cell recognition of the Qa-1 determinant modifier peptide.
    Cotterill LA; Stauss HJ; Millrain MM; Pappin DJ; Rahman D; Canas B; Chandler P; Stackpoole A; Simpson E; Robinson PJ; Dyson PJ
    Eur J Immunol; 1997 Sep; 27(9):2123-32. PubMed ID: 9341749
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Creating CTL targets with epitope-linked beta 2-microglobulin constructs.
    Uger RA; Barber BH
    J Immunol; 1998 Feb; 160(4):1598-605. PubMed ID: 9469415
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tumorigenicity and immunogenicity of murine tumor cells expressing an MHC class II molecule with a covalently bound antigenic peptide.
    Ladányi A; Nishimura MI; Rosenberg SA; Yang JC
    J Immunother; 2000 Jan; 23(1):36-47. PubMed ID: 10687136
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Chimeric beta2 microglobulin/CD3zeta polypeptides expressed in T cells convert MHC class I peptide ligands into T cell activation receptors: a potential tool for specific targeting of pathogenic CD8(+) T cells.
    Margalit A; Fishman S; Berko D; Engberg J; Gross G
    Int Immunol; 2003 Nov; 15(11):1379-87. PubMed ID: 14565936
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Glu227-->Lys substitution in the acidic loop of major histocompatibility complex class I alpha 3 domain distinguishes low avidity CD8 coreceptor and avidity-enhanced CD8 accessory functions.
    Shen L; Potter TA; Kane KP
    J Exp Med; 1996 Nov; 184(5):1671-83. PubMed ID: 8920857
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.